In the OPTIMAL trial, Asian patients with chemonaïve NSCLC with EGFR mutations were randomized to erlotinib 150 mg/day or gemcitabine plus carboplatin [50]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.